Bryostatin 1 - GPC Biotech
Alternative Names: BMY 45618; Bryol; NSC 339555Latest Information Update: 25 Sep 2021
Price :
$50 *
At a glance
- Originator Arizona State University
- Developer GPC Biotech AG
- Class Antidementias; Antidepressants; Antineoplastics; Antiparkinsonians; Behavioural disorder therapies; Macrocyclic compounds; Small molecules; Vascular disorder therapies
- Mechanism of Action Protein kinase C stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Chronic lymphocytic leukaemia; Graft-versus-host disease; Malignant melanoma; Non-Hodgkin's lymphoma; Oesophageal cancer; Renal cancer